---
title: "Aldeyra Therap (ALDX.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ALDX.US/norm.md"
symbol: "ALDX.US"
name: "Aldeyra Therap"
parent: "https://longbridge.com/en/quote/ALDX.US.md"
datetime: "2026-05-21T22:31:26.565Z"
locales:
  - [en](https://longbridge.com/en/quote/ALDX.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ALDX.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ALDX.US/norm.md)
---

# Aldeyra Therap (ALDX.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.0572 | -0.1074 | -0.1279 | -0.1627 | -0.1658 |
| ROE | -31.97% | -55.29% | -58.84% | -65.72% | -59.01% |
| Revenue | - | - | - | - | - |
| Net income | -3.45M | -6.46M | -7.69M | -9.77M | -9.93M |
| Operating income | -3.55M | -6.67M | -8.00M | -10.17M | -10.43M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 66.48M | 72.06M | 77.80M | 84.96M | 93.20M |
| Leverage | 1.58 | 1.63 | 1.58 | 1.54 | 1.47 |
| BVPS | 0.6989 | 0.7355 | 0.8185 | 0.9208 | 1.06 |
| Turnover | - | - | - | - | - |
| Cash & STI | 65.00M | 70.04M | 75.30M | 81.92M | 90.06M |
| Inv & Rec | - | - | - | - | - |
| LT assets | 209262.00 | 275861.00 | 340977.00 | 404660.00 | 466942.00 |
| Net debt | -49.49M | -54.51M | -59.75M | -66.36M | -74.49M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -5.11M | -5.30M | -7.02M | -8.56M | -12.47M |
| Investing CF | - | 16.00M | 25.00M | -554126.00 | 7.29M |
| Financing CF | 71140.00 | 0.0000 | 120746.00 | 0.0000 | 1.00M |
| Free CF | -6.13M | -3.33M | -2.99M | -5.98M | -7.98M |
| OCF coverage | - | - | - | - | - |
| Repaid & issued | - | - | - | - | - |
| CapEx | - | - | - | - | - |